What if you could inject a significantly smaller dose of toxic chemotherapy directly into a malignant tumor site and stop its growth? The potential benefits range from greatly reduced drug side effects, to a complete remission of the disease, to an inoculation against future cancer growth. For Intensity Therapeutics, these results have already been shown in mice. The company is now raising funds to advance to clinical trials, which have been fast-tracked by the U.S. Food and Drug Administration.

Intensity Therapeutics, Inc. is a biotechnology company whose mission is to greatly extend the lives of patients with solid tumor cancers. The company has partnered with the National Cancer Institute to test its pioneering new immunotherapy approach to treat cancer called in situ vaccination.

The Company’s products consist of proprietary formulations of proven chemotherapy drugs that are injected directly into tumors. Early preclinical data show that these products, when injected directly into tumors, result in significantly greater tumor growth inhibition and increased survival compared to conventionally IV-delivered chemotherapy. The technology attenuates (kills) a tumor in a manner that allows for the adaptive immune system to recognize the cancer, to attack untreated tumors, and to prevent cancer from returning.


Lew Bender Intensity Therapeutics

Lewis H. Bender

Founder and CEO

Bender earned degrees in Chemical Engineering from MIT, an MA in International Studies from UPenn and an MBA from UPenn’s Wharton School of Business. He is the former CEO of Interleukin Genetics, a personalized medicine company, and held various roles from business development and manufacturing to CTO and CEO of Emisphere Technologies, a drug delivery company. Read more about Lewis H. Bender

Read More Less
Ian Walters IT

Ian B. Walters, MD

Vice President and CMO

Dr. Walters has over 15 years of oncology/immunology drug development experience, most recently at Bristol-Myers Squibb. He has worked in multiple biotech companies on corporate development, translational medicine, clinical development and medical affairs including Millennium Pharmaceuticals, and has been a consultant to biotech, pharma and investment companies specializing in the evaluation, prioritization, and development of innovative technologies to treat severe diseases. Before entering the private sector, Dr. Walters was a lead investigator at the Rockefeller University. He received his MD from the Albert Einstein College of Medicine and an MBA from UPenn’s Wharton School of Business.

Read More Less
Doug Hanahan PhD Scientific Advisory Board, Intensity Therapeutics

Douglas Hanahan, Ph.D.

Scientific Advisory Board

Dr. Hanahan is a full professor at the École Polytechnique Fédérale de Lausanne (EPFL), the Swiss Federal Institute of Technology Lausanne. In addition, Dr. Hanahan is director of the Swiss Institute for Experimental Cancer Research (ISREC), part of EPFL; and is vice-director of the new multi-institutional Swiss Cancer Center Lausanne. He received a Ph.D. in biophysics from Harvard, where he was a Harvard Junior Fellow. As a graduate student and as a faculty member at Cold Spring Harbor Laboratory, NY, he developed innovative models for studying human cancer. Dr. Hanahan continued this work when he joined the Department of Biochemistry and Biophysics and Hormone Research at the University of California, San Francisco, CA, USA in 1988. He became head of ISREC in 2009. Dr. Hanahan’s accomplishments in the field of oncology and the tumor microenvironment have been recognized by his election to several honor societies, such as the American Academy of Arts & Sciences (2007), the Institute of Medicine of the US National Academies (2008), the US National Academy of Science (2009), and the European Molecular Biology Organization (2010). Dr. Hanahan’s paper, “The Hallmarks of Cancer,” which he co-authored with Robert Weinberg and published in the journal Cell in January 2000, is one of the seminal papers in the history of cancer research, and one of Cell’s most cited articles.

Read More Less
Mario Sznol, Scientific Advisory Board, Intensity Therapeutics

Mario Sznol, MD

Scientific Advisory Board

Dr. Sznol is currently professor of internal medicine at Yale University School of Medicine, Smillow Cancer Center, co-director of the Yale Melanoma Program, and co-director of Yale SPORE in Skin Cancer. He is an investigator in several clinical trials at the Yale Cancer Center, including those focusing on immunotherapy and novel agents. Dr. Sznol has an international reputation in cancer drug development with expertise in cancer immunotherapy and the treatment of patients with melanoma and renal cell carcinoma. Dr. Sznol received his undergraduate degree from Rice University, trained in internal medicine at Baylor College of Medicine in Houston, Texas, and completed a medical oncology fellowship in the Department of Neoplastic Diseases in Mount Sinai Hospital, New York. He spent the next twelve years in the Biologics Evaluation Section (BES), Investigational Drug Branch of the Cancer Therapy Evaluation Program at the National Cancer Institute (NCI) and was head of the BES from 1994-1999.

Read More Less
Riccardo Lencioni, Scientific Advisor, Intensity Therapeutics

Riccardo Lencioni, MD, FSIR, EBIR

Scientific Advisory Board

Dr. Riccardo Lencioni is professor of clinical radiology at the University of Miami Miller School of Medicine and director of the Interventional Oncology Research Group. Previously Dr. Lencioni was professor and director of Diagnostic Imaging and Intervention at Pisa University School of Medicine in Pisa, Italy. He is the founder of the International Liver Cancer Association (ILCA) and served as the ILCA executive secretary. Dr. Lencioni has also served as chairman of the World Conference of Interventional Oncology, a network of interventional oncologists dedicated to the development of treatment approaches based on imaging, such as intratumoral delivery. He has been involved in the development of recommendations for the research and clinical management of hepatocellular carcinoma, and recently co-authored the white papers, “Design and Endpoints in Clinical Trials in Hepatocellular Carcinoma” (2008), Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma” (2010), and “EASL-EORTC Clinical Practice Guidelines: Management of Hepatocellular Carcinoma” (2012). Riccardo Lencioni has published 190 articles in peer-reviewed international journals and 61 textbook chapters, and is the editor of nine books.

Read More Less

News and Press

Poster Presentation - News Release

AARC Meeting, April 19, 2016

Chief Medical Officer Dr. Ian B Walters will present mechanism of action and other data in a poster session at the American Academy of Cancer Research (AACR) meeting on April 19, 2016

Poster Presentation - Link to Poster

AARC Meeting, April 19, 2016

See the poster presented by Dr. Ian B. Walters at the American Academy of Cancer Research (AACR) meeting on April 19, 2016

Poster Presentation - Link to Poster

National Cancer Institute’s annual Cancer Immunology and Immunotherapy Meeting, October 9 -10, 2014 in Bethesda, MD

Novel cell penetrating formulation of cytotoxic agents administered intratumorally causes complete regression of large tumors and stimulation of an adaptive immune response in BALB/c syngeneic mice inoculated subcutaneously with murine CT26 colon cancer

Intensity Therapeutics looks to raise USD 7.5m to bring intratumoral chemo to clinical trials

BioPharm Insight, March 26, 2014

Announcement of Intensity Therapeutics establishing a cooperative research and development agreement with the NIH's NCI Vaccine Branch